Tempus AI is in a powerful recovery uptrend that has not yet reclaimed its longer-term highs: the stock is up 65.76% over six months and 53.11% over three months, yet still down 10.60% over the trailing year, and at $77.84 it sits at roughly 59.2% of its 52-week range between a $40.77 low and a $104.32 high. That positioning — well off the low but still about 25% below the high — means the stock is neither an oversold value opportunity nor a fully extended momentum leader, but rather a name in the middle of a volatile re-rating where the burden of proof sits with the bulls to push through prior supply. The 59.76% maximum drawdown underscores how violently this name can de-rate, so trend-followers should treat the recovery as real but fragile. Recent momentum is decisively positive and accelerating: the stock gained 27.09% in the past month versus a 0.96% decline in SPY, producing relative strength of +28.05 percentage points, and the three-month relative strength of +51.11 points is even more striking. This one-month surge (+27.09%) is directionally consistent with, not divergent from, the six-month gain (+65.76%), suggesting genuine trend continuation rather than a mean-reversion bounce, though the 3.14% single-day drop on the most recent session (from $80.36 to $77.84) hints at near-term profit-taking after the run to $80.36. With volume of 9.31 million shares and a short ratio of 3.98, there is ample fuel for either continued squeeze-driven upside or sharp unwinds if momentum stalls. Key levels are clearly defined: resistance sits at the 52-week high of $104.32, roughly 34% above the current $77.84 price, and a decisive breakout above that level would signal the market is fully underwriting the Personalis-driven growth story and could open a new leg higher. Support rests at the 52-week low of $40.77, about 47.6% below current levels, and a breakdown toward that zone would signal the recovery has failed and the longer-term downtrend has resumed. With a beta of 3.724 — meaning the stock is roughly 3.7 times as volatile as the market — position sizing must be conservative; a 1% SPY move implies a ~3.7% TEM move, so risk management and stop discipline are far more consequential here than for a typical large-cap healthcare name.

Tempus's revenue trajectory is clearly growing but decelerating at the margin: Q1 2026 revenue of $348.12 million rose 36.12% year over year from $255.74 million in Q1 2025, continuing a multi-quarter climb from $314.64 million in Q2 2025, $334.21 million in Q3 2025, and $367.21 million in Q4 2025. The sequential pattern is uneven — Q4 2025 was the peak at $367.21 million before Q1 2026 dipped to $348.12 million — which is consistent with seasonality but also suggests the growth rate, while robust in the mid-30s, is not accelerating. The Diagnostics segment, at $261.10 million, is the dominant revenue engine and the core of the investment case, meaning overall growth is highly levered to diagnostic volume and reimbursement rather than to a diversified mix. For the investment case, mid-30s% growth at scale is attractive, but the market is clearly pricing in sustained execution, so any deceleration below roughly 30% would likely pressure the multiple. Profitability remains the central issue: Q1 2026 net income was -$125.92 million on $348.12 million of revenue, a net margin of -36.17%, and EPS of -$0.70, while gross margin was 62.72% ($218.34 million of gross profit). Gross margin has been relatively stable in the low-60s across recent quarters (61.61% in Q3 2025, 61.99% in Q2 2025, 62.72% in Q1 2026), which is a healthy level for a diagnostics-and-data business, but operating expenses of $295.66 million — including $45.92 million of R&D and $212.59 million of SG&A — overwhelm that gross profit and drive an operating margin of -22.21%. The Q4 2025 quarter showed a brief EBITDA-positive print of -$21.95 million (still negative) and an unusually high 89.74% gross margin that appears distorted by cost classification, so the cleaner read is that the company is structurally unprofitable but with a gross-margin base that could support profitability if operating leverage materializes. Balance sheet and cash flow present a mixed picture: the current ratio of 3.13 and quick ratio of 3.15 indicate strong short-term liquidity, and cash at the end of Q1 2026 was $521.17 million, but debt-to-equity of 2.70 and a debt ratio of 0.618 signal meaningful leverage, and free cash flow remains deeply negative at -$81.48 million in Q1 2026 and -$216.50 million on a trailing-twelve-month basis. ROE of -49.87% and ROA of -8.55% confirm that capital is being consumed rather than generated, and with stock-based compensation of $52.71 million in the quarter, a meaningful portion of the cash burn is non-cash but still dilutive. The company can fund itself internally for now given the $521 million cash balance, but the combination of negative FCF, high leverage, and a 3.72 beta means external financing risk — and dilution risk — remains a live concern if the burn does not narrow.